Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
Author:
Publisher
Elsevier BV
Subject
General Medicine,Surgery
Reference100 articles.
1. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy;Cardoso;J Natl Cancer Inst,2009
2. Herceptin: mechanisms of action and resistance;Nahta;Cancer Lett,2006
3. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer;Witton;J Pathol,2003
4. Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review;Rosen;Oncologist,2010
5. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth receptor 2 testing in breast cancer;Wolff;J Clin Oncol,2007
Cited by 86 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment;Current Drug Delivery;2024-08
2. Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo;Biological Procedures Online;2023-06-27
3. Evolution-Informed Strategies for Combating Drug Resistance in Cancer;International Journal of Molecular Sciences;2023-04-04
4. Recent advances in the role of endogenous hydrogen sulphide in cancer cells;Cell Proliferation;2023-03-16
5. Strobilanthes crispus elicits anti-tumor immunogenicity in in vitro and in vivo metastatic breast carcinoma;PLOS ONE;2022-08-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3